Last weekend Dr. Chuck Jackson of Overall Ovations lead OSCO’s 2017 Board Retreat. We are feeling confident about the year to come and can’t wait to help Oklahoma’s oncology staff care for their patients. Click Here for pictures of the … Continued
Following review and discussion of L36711 Novitas will be making revisions to the policy. Please continue to watch our website. As a reminder, the LCD Reconsideration Process is the appropriate mechanism for interested parties to request a revision to a … Continued
U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (TAFINLAR® and MEKINIST®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.